State AGs Announce $17.85M Drug Price Fixing Settlements
Summary
A multistate coalition of 48 states and territories, led by Attorney General Phil Weiser, announced settlements totaling $17.85 million with Lannett Company and Bausch Health over allegations of drug price fixing. The settlements require cooperation with ongoing litigation and internal reforms. A new lawsuit was also filed against Novartis and Sandoz.
What changed
Attorney General Phil Weiser, joined by 47 other states and territories, has announced settlements totaling $17.85 million with Lannett Company and Bausch Health. These settlements resolve allegations that both companies engaged in long-running conspiracies to artificially inflate prices and limit competition for generic prescription drugs. As part of the agreements, both companies will cooperate with ongoing antitrust litigation against other defendants and implement internal reforms to ensure compliance with antitrust laws. This action follows previous settlements with Apotex and Heritage Pharmaceuticals, totaling $49.1 million, and precedes the first trial in the multistate litigation anticipated in late 2026.
Regulated entities, specifically drug manufacturers and pharmaceutical companies, should be aware of these enforcement actions and the ongoing multistate litigation. The settlements highlight the significant financial penalties and legal scrutiny associated with price-fixing and anti-competitive practices in the pharmaceutical market. Companies involved in the generic drug market should review their pricing and competition practices to ensure compliance with antitrust laws. Consumers who purchased generic prescription drugs manufactured by Lannett or Bausch between May 2009 and December 2019 may be eligible for compensation. Additionally, a new lawsuit has been filed against Novartis and Sandoz, indicating continued enforcement efforts in this sector.
Source document (simplified)
Attorney General Phil Weiser announces settlements with Lannett and Bausch totaling $17.85 million over conspiracies to inflate drug prices and limit competition
The attorney general also files new complaint against Novartis and Sandoz
Feb. 2, 2026 (DENVER) – Attorney General Phil Weiser today joined a bipartisan, multistate coalition of 48 states and territories in announcing settlements with Lannett Company, Inc. (“Lannett”) and Bausch Health US, LLC and Bausch Health Americas, Inc. (“Bausch”), totaling $17.85 million. The settlements resolve allegations that both companies engaged in widespread, long-running conspiracies to artificially inflate and manipulate prices, limit competition, and unreasonably restrain trade for numerous generic prescription drugs.
Under the settlement agreements, Lannett and Bausch have agreed to cooperate with the states’ ongoing antitrust litigation against other corporate defendants and individual executives involved in the alleged misconduct. Both companies have also committed to internal reforms designed to promote fair competition and ensure compliance with antitrust laws.
“Coloradans and consumers across the country deserve fair prices for lifesaving medications, not inflated costs driven by illegal backroom deals. These settlements hold drug manufacturers accountable for harming patients and families, return money to consumers, and reinforce that companies doing business in Colorado must follow the law,” said Attorney General Weiser. “My office will continue working with our state and national partners to protect competition and ensure the pharmaceutical market works for people — not price-fixers.”
The Lannett and Bausch settlements follow earlier settlements with Apotex and Heritage Pharmaceuticals, which together totaled $49.1 million. These agreements come as the states prepare for the first trial in the multistate litigation, currently anticipated to be held in Hartford, Connecticut, in late 2026.
Those who purchased a generic prescription drug manufactured by Lannett or Bausch between May 2009 and December 2019, may be eligible for compensation. To determine eligibility, call 1-866-290-0182 (toll-free), email info@AGGenericDrugs.com, or visit www.AGGenericDrugs.com (opens new tab).
Also today, 42 states and territories, including Colorado, filed a new lawsuit against Novartis, and its generic subsidiary Sandoz, alleging a systemic campaign to conspire with other generic manufacturers to fix prices, allocate markets and rig bids for 31 different generic drugs. The complaint further alleges that Novartis took steps to fraudulently transfer and drain assets from Sandoz and spin off Sandoz to shield Novartis from liability in the three previously filed state antitrust complaints against the company.
The multistate cases arise from coordinated investigations involving extensive documentary evidence, phone records, and cooperation from multiple industry insiders. The states allege that executives from competing generic drug manufacturers regularly communicated and met at industry events, social gatherings, and private meetings to coordinate pricing and suppress competition.
Across three related antitrust complaints, the states allege conspiracies involving dozens of corporate defendants, numerous senior executives, and more than 80 generic prescription drugs accounting for billions of dollars in U.S. sales. Evidence obtained by the states includes millions of documents, detailed call records, and contemporaneous notes kept by cooperating witnesses that memorialize discussions among competitors and internal company meetings over several years.
The complaints describe how defendants used coded language such as “fair share,” “playing nice in the sandbox,” and “responsible competitor” to disguise unlawful agreements that discouraged competition, raised prices, and enforced a culture of collusion throughout the generic drug industry.
States and territories settling today with Lannett and Bausch include: Alaska, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Northern Mariana Islands, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Utah, U.S. Virgin Islands, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming, and Puerto Rico.
States and territories filing the new complaint against Novartis and Sandoz include: Alaska, Arizona, California, Connecticut, Colorado, Delaware, District of Columbia, Idaho, Illinois, Indiana, Iowa, Kentucky, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Northern Mariana Islands, Ohio, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Dakota, Tennessee, Vermont, U.S. Virgin Islands, Virginia, Washington, West Viginia, Wisconsin, and Wyoming.
Read the Lannett and Bausch settlement (PDF).
Read the Novartis and Sandoz complaint (PDF).
Media Contact:
Lawrence Pacheco
Chief Communications Officer
(720) 508-6553 office
lawrence.pacheco@coag.gov
Most Recent
Attorney General Weiser to send settlement funds to Colorado PetSmart workers
Feb. 17, 2026 (DENVER) – More than 60 former PetSmart workers will soon receive checks in the mail from a November 2025 settlement reached with PetSmart. Attorney General Phil Weiser sued the company in July 2025, alleging it trapped dog […]
Attorney General Phil Weiser statement on the states not reaching agreement on future of Colorado River
Feb. 13, 2026 (DENVER) — Attorney General Phil Weiser today issued the following statement in regarding the end of negotiations over future management of the Colorado River without an agreement: “I am disappointed that the seven Basin States could not reach a consensus agreement […]
Attorney General Phil Weiser statement on U.S. EPA revoking a key policy to combat climate change
Feb. 12, 2026 (DENVER) — Attorney General Phil Weiser today issued the following statement in response to the U.S. Environmental Protection Agency’s final rule rescinding the 2009 endangerment finding, which determined that greenhouse gas emissions from motor vehicles contribute to […]
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Government alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when CO Attorney General Press Releases publishes new changes.